CD274 and non-small cell lung carcinoma: With this view in mind, Conforti et al. performed 2 meta‐analyses: (A) RCTs which compared a combination of anti‐PD‐1/anti‐PD‐L1 agents and chemotherapy with chemotherapy and (B) RCTs of first‐line systemic treatment for advanced NSCLC that used PD‐1/PD‐L1 inhibitors either alone or along with chemotherapy.